style="color:#c41230;">Pausing for breath

EMIS Group 14 April 2016 Institutional Update

EMIS Group

Pausing for breath

FY15 results

Software & comp services

 

14 April 2016

Price

1,021p

Valuation

1,060p

Difference

3.8%

Market cap

£646m

Net debt (£m) at end FY15

9.1

Shares in issue

63.3m

Free float

74.7%

Code

EMIS

Primary exchange

AIM

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(4.6)

(10.2)

17.8

Rel (local)

(4.1)

(10.7)

28.5

52-week high/low

1155p

860p

Business description

EMIS is a clinical software supplier to the primary care market in the UK (supplying over 50% of UK GP practices), a software supplier to UK pharmacies, and through several acquisitions also supplies specialist and acute care software.

Next events

AGM

26 April 2016

H116 trading update

July 2016

H116 results

2 September 2016

Analysts

Katherine Thompson

+44 (0)20 3077 5730

Dan Ridsdale

+44 (0)20 3077 5729

EMIS managed to achieve solid profits in FY15 despite the previously flagged weakness in the Secondary Care business. The company has taken action to restructure this business and continues to expect revenue and profit growth at a group level in FY16. We have trimmed our forecasts to reflect the lower revenue base in FY15, with our normalised EPS forecasts reducing by 3.0% in FY16 and 2.3% in FY17. Improving momentum in Secondary Care contract wins and further wins in CCMH and integrated healthcare could drive upside from this point.

Year end

Revenue (£m)

EBITDA (£m)

EPS* (p)

Net (debt) / cash

P/E (x)

Yield (%)

12/14

137.6

47.6

42.8

(11.8)

23.9

1.8

12/15

155.9

52.0

46.0

(9.1)

22.2

2.1

12/16e

166.8

56.1

48.9

2.2

20.9

2.2

12/17e

176.9

59.6

52.2

23.0

19.5

2.3

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

FY15 profitability maintained despite revenue miss

FY15 results were in line with downwardly revised expectations from the January trading update. Good performances from Primary Care, CCMH and Community Pharmacy were offset by a lower level of contract signings in Secondary Care, to result in revenue growth of 13% y-o-y (5% organic) and adjusted operating profit of £36.6m (23.4% margin). To improve performance of the Secondary Care business, divisional management, sales and product development have been restructured.

FY16 forecasts trimmed

The company expects to achieve mid- to high single digit revenue growth in FY16 with adjusted operating profit in the high £30m/low £40m range. We have trimmed our revenue forecasts to factor in the lower Secondary Care revenues in FY15 for FY16; this is partially offset by restructuring of this business. We reduce our FY16 adjusted operating profit forecast by 4.3% to £39.2m and reduce our EMIS adjusted EPS forecast by 3.3% in FY16 and 2.5% in FY17 (normalised EPS -3.0% and -2.3% respectively).

Valuation: Secondary Care holds key to upside

The stock is trading at a c 8% premium to peers on an FY17e normalised EPS, which is fair in our view given EMIS’s superior profitability, supported by a dividend yield of c 2%. To see upside from here, we need there to be momentum in Secondary Care contract wins and consequently improving profitability, more integrated healthcare contract wins and beating market share targets in CCMH from winning more of the North New and Refresh contracts. Longer term, the roll-out to the newly signed Lloyds pharmacies should provide a boost to profitability.

Review of FY15 results

EMIS reported FY15 revenues in line with the guidance given in its January trading update, generating year-on-year growth of 13% (organic growth 5%), and 20% growth in recurring revenues. Revenues came in lower than originally expected due to weaker performance from the Secondary Care business; despite this, the company reported cash R&D adjusted operating profit substantially in line with expectations. Reported operating profit was reduced by a £16.2m goodwill impairment charge for the Ascribe acquisition and a £2.3m impairment charge for the company’s minority investment in Pharmacy2U. A combination of factors (unwinding of deferred income, reduced bonus accrual, slightly higher capex and tax) meant that net debt was £6.8m higher than our forecast. The company announced a final dividend of 10.6p, to result in a full year dividend of 21.2p.

Exhibit 1: FY15 results highlights

£000s

FY15e

FY15a

Change

y-o-y

Revenues

160,488

155,898

-2.9%

13.3%

Normalised operating profit*

37,577

37,123

-1.2%

6.7%

Reported operating profit

30,442

11,430

-62.5%

-60.7%

Adjusted operating profit**

36,897

36,553

-0.9%

12.0%

Normalised EPS - p

45.7

46.0

0.6%

7.5%

Reported EPS - p

36.9

7.2

-80.4%

-79.5%

Adjusted EPS - p

44.0

45.1

2.5%

14.5%

Net cash/(debt)

(2,338)

(9,109)

289.6%

-22.9%

Source: EMIS, Edison Investment Research. Note: *Excludes amortisation of acquired intangibles, exceptionals and share-based payments. **EMIS adjusted: as for normalised, but accounts for development costs on a cash basis.

Business update
Primary and Community care (60% of FY15 revenues)

GP market share increased to 54.9% (5,210 practices) up from 53.1% at the end of 2014. The EMIS Web rollout is complete in England and for EMIS LV users in Wales. In Northern Ireland, EMIS Web will be rolled out to half the sites in 2016 and the remaining sites in 2017. In Scotland, it is expected that practices using EMIS PCS will move over to EMIS Web – the procurement method has not yet been finalised but is expected to take place in 2016. The UK MoD contract (based on a variant of EMIS PCS) was extended until April 2019, with discussions underway to move to EMIS Web.

The number of CCGs1 using solely EMIS GP software has risen from 32 to 44 over the year (21% share of CCGs). This enables better data sharing within the CCG and makes the use of EMIS Web elsewhere in the healthcare community more attractive.

Clinical commissioning group

The company had hoped to win some new GP customers when the contracts assigned as part of the National Programme (NPfIT) come to an end in July 2016. TPP won close to 2,000 contracts in the North, Midlands and East of England (NME) as subcontractor to CSC, the local service provider (LSP), whereas EMIS was never part of NPfIT. When the time came to renew the contracts, most CCGs decided to keep their practices on TPP software so the chance to for EMIS to win new business did not arise.

The CCMH2 business grew its market share to 12%, up from 8% at the end of FY14 and beating its year-end target of 10%. The target for end FY16 is 15%. The company won contracts worth more than £10m in the year. The London and South CCMH procurement process is now complete; the next area to target is the NME – for both the refresh of sites that received software as part of NPfIT and for those practices that did not receive any software at the time. This amounts to c 180 entities that will need to select or renew CCMH software over the next couple of years. New contract wins in 2015 include East Lancashire Hospitals NHS Trust, Central Manchester Foundation Trust, Pennine Acute Hospitals NHS Trust and Southport & Ormskirk Hospitals NHS Trust. In 2016, the company has also signed a contract with South Tyneside NHS Trust and extended a contract with Stockport NHS Foundation Trust.

Child Community and Mental Health

Secondary and Specialist care (27% of FY15 revenues)

Secondary Care won fewer new contracts than expected, which negatively affected revenues and profits for the year. A new management team for this business was appointed in 2015, and changes were made to refocus the business. This includes improving the software release quality and restructuring the sales team to focus on small and medium-sized deals while continuing to work on large deals. The product roadmap has been reviewed in detail and consequently refreshed, to provide a rationalised product set and to support convergence within healthcare. Product development has been restructured, with the majority to be undertaken by the new EMIS India development centre and the closure of development operations in Australia and New Zealand (by December 2017) and Kenya (by June 2016).

EMIS Health – Specialist and Care business performed well in the year, boosted by recent acquisitions Indigo4 and Medical Imaging. The Specialist part of the business provides diabetic eye screening software and other ophthalmology-related solutions. Public Health England announced in January that it would be seeking a single software solution in England for diabetic eye screening – with its 79% market share in England (by programme), EMIS is in a strong position to tender for this business. Medical Imaging’s diabetic eye screening and ophthalmology imaging services have been rebranded as EMIS Care.

Community Pharmacy (13% of FY15 revenues)

Market share was maintained at 36% of the combined independent and supermarket market. EMIS recently announced that it signed a new five-year contract with AAH, which will incorporate c 1,800 Lloyds pharmacies for the first time and should take EMIS’s community pharmacy market share to nearly 50% over the next 18 months. Management does not expect to see a profit contribution from this new business until 2018. The business has spent c £1m developing its next generation ProScript Connect software during the year – this is in pilot and is scheduled to launch in 2016. EMIS Web is being trialled by some pharmacies in anticipation of them being able to offer primary care services, with launch scheduled for 2017.

Outlook and changes to forecasts

In FY16 the company expects to generate revenues in the upper £160m range, with operating profit in the higher £30m/low £40m range. Net debt is expected to move to a net cash position (low single digit £m) by the end of FY16. The company has increased its capex budget for FY16 to c £10m (versus £6m in FY15) with roughly half of this allocated to purchase of hosting assets. We have revised down our revenue forecasts, reflecting the weaker performance in Secondary Care. At the operating profit level, we have assumed some cost savings from the Secondary Care restructuring and do not yet factor in material upside from the recent Pharmacy contract win. Overall, this results in a 3.0% cut to FY16e normalised EPS and 3.3% cut to EMIS adjusted EPS. In FY17e, we reduce normalised EPS by 2.3% and EMIS adjusted EPS by 2.5%. The company expects to move to a low single-digit million net cash position by the end of FY16.

Exhibit 2: Changes to forecasts

£'000s

FY16e

FY16e

Change

y-o-y

FY17e

FY17e

Change

y-o-y

Old

New

Old

New

Revenues

170,038

166,805

-1.9%

7.0%

179,058

176,856

-1.2%

6.0%

Normalised operating profit

41,103

39,971

-2.8%

7.7%

43,440

42,563

-2.0%

6.5%

Reported operating profit

33,968

32,314

-4.9%

182.7%

36,304

34,906

-3.9%

8.0%

Adjusted operating profit

41,016

39,249

-4.3%

7.4%

43,923

42,344

-3.6%

7.9%

Normalised EPS - p

50.4

48.9

-3.0%

6.3%

53.5

52.2

-2.3%

6.8%

Reported EPS - p

41.5

39.4

-5.2%

443.6%

44.6

42.7

-4.3%

8.5%

Adjusted EPS - p

49.4

47.8

-3.3%

5.9%

53.2

51.9

-2.5%

8.6%

Net cash/(debt)

15,986

2,244

-86.0%

-124.6%

38,302

22,995

-40.0%

924.6%

Source: Edison Investment Research

 

Exhibit 3: Financial summary

£'000s

2012

2013

2014

2015

2016e

2017e

Year end 31 December

PROFIT & LOSS

Revenue

 

 

86,333

105,542

137,639

155,898

166,805

176,856

Cost of Sales

(10,891)

(11,780)

(12,782)

(12,955)

(17,414)

(18,994)

Gross Profit

75,442

93,762

124,857

142,943

149,390

157,862

EBITDA

 

 

33,178

38,885

47,645

51,964

56,129

59,584

Operating Profit (before amort. of acq. intang, SBP and except.)

27,619

30,482

34,787

37,123

39,971

42,563

Amortisation of acquired intangibles

(2,983)

(4,198)

(6,269)

(6,509)

(6,657)

(6,657)

Exceptionals

(435)

(1,144)

873

(18,500)

0

0

Share-based payments

(90)

(195)

(270)

(684)

(1,000)

(1,000)

Operating Profit

24,111

24,945

29,121

11,430

32,314

34,906

Net Interest

(76)

(242)

(543)

(449)

(250)

(150)

Profit Before Tax (norm)

 

 

27,567

30,172

34,206

36,625

39,701

42,423

Profit Before Tax (FRS 3)

 

 

24,059

24,635

28,540

10,932

32,044

34,766

Tax

(4,625)

(4,706)

(5,719)

(5,558)

(6,569)

(7,127)

Profit After Tax (norm)

23,191

25,179

27,617

29,801

31,562

33,726

Profit After Tax (FRS3)

19,434

19,929

22,821

5,374

25,475

27,639

Average Number of Shares Outstanding (m)

58.2

59.4

62.8

62.7

62.8

62.8

EPS - normalised (p)

 

 

39.0

41.4

42.8

46.0

48.9

52.2

EPS - FRS 3 (p)

 

 

32.5

32.6

35.3

7.2

39.4

42.7

Dividend (p)

14.2

16.0

18.4

21.2

22.4

23.2

Gross Margin (%)

87.4%

88.8%

90.7%

91.7%

89.6%

89.3%

EBITDA Margin (%)

38.4%

36.8%

34.6%

33.3%

33.6%

33.7%

Operating Margin (before GW and except.) (%)

32.0%

28.9%

25.3%

23.8%

24.0%

24.1%

BALANCE SHEET

Fixed Assets

 

 

77,673

153,838

166,415

143,546

137,831

129,554

Intangible Assets

52,789

126,468

139,397

121,383

113,768

105,591

Tangible Assets

22,144

24,610

24,313

22,032

23,932

23,832

Other fixed assets

2,740

2,760

2,705

131

131

131

Current Assets

 

 

27,538

27,046

37,221

39,800

49,338

71,599

Stocks

1,243

1,431

1,550

1,206

1,206

1,206

Debtors

15,188

21,448

28,732

33,893

35,878

38,388

Cash

11,107

4,167

6,939

4,701

12,254

32,005

Current Liabilities

 

 

(30,598)

(54,530)

(67,665)

(63,819)

(58,819)

(60,578)

Creditors

(30,202)

(46,628)

(54,763)

(51,960)

(48,960)

(51,719)

Short term borrowings

(396)

(7,902)

(12,902)

(11,859)

(9,859)

(8,859)

Long Term Liabilities

 

 

(10,548)

(22,231)

(21,063)

(12,481)

(10,681)

(10,681)

Long term borrowings

(3,000)

(9,756)

(5,854)

(1,951)

(151)

(151)

Other long term liabilities

(7,548)

(12,475)

(15,209)

(10,530)

(10,530)

(10,530)

Net Assets

 

 

64,065

104,123

114,908

107,046

117,669

129,894

CASH FLOW

Operating Cash Flow

 

 

32,732

38,725

44,856

42,711

54,144

59,832

Net Interest

(60)

(580)

(445)

(422)

(150)

(50)

Tax

(4,566)

(5,073)

(5,247)

(6,896)

(8,139)

(8,697)

Capex

(18,342)

(15,025)

(15,161)

(14,058)

(17,100)

(15,400)

Acquisitions/disposals

(512)

(57,315)

(9,959)

(4,587)

(3,000)

0

Financing

(1,816)

27,212

(1,578)

492

(600)

(500)

Dividends

(7,735)

(9,146)

(10,792)

(14,532)

(13,802)

(14,435)

Net Cash Flow

(299)

(21,202)

1,674

2,708

11,353

20,751

Opening net debt/(cash)

 

 

(8,026)

(7,711)

13,491

11,817

9,109

(2,244)

HP finance leases initiated

0

0

0

0

0

0

Other

(16)

0

0

0

0

0

Closing net debt/(cash)

 

 

(7,711)

13,491

11,817

9,109

(2,244)

(22,995)

Source: EMIS, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com.

DISCLAIMER Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)4 8948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)4 8948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Share this with friends and colleagues

You may be interested in